Bicalutamide: Brands, Price & Uses in Bangladesh

Approved Indication

Bicalutamide is indicated, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for the treatment of Stage D2 metastatic carcinoma of the prostate.

Guideline-Supported / Additional Uses

• Combination therapy with an LHRH analog (as part of combined androgen blockade) for locally advanced, non-metastatic prostate cancer, including alongside radiotherapy, per specialist oncology guidelines.
• Use as monotherapy in certain specialist-directed regimens, under close monitoring for gynecomastia and breast pain; this is not an FDA-approved use of the 150 mg strength.

Bicalutamide is not indicated for use in women and has no established role outside the management of prostate cancer.

Dosage of Bicalutamide should be individualized by a specialist physician based on indication and response. See the Dosage and Administration fields below for further detail.

No dosage adjustment is generally required for renal impairment or mild-to-moderate hepatic impairment; use with caution and monitor liver function in patients with severe hepatic impairment (see Precautions and Warnings).

Very Common

Hot flashes, generalized pain, back pain, weakness (asthenia), pelvic pain, constipation, and gynecomastia/breast tenderness (especially with monotherapy).

Common

Nausea, peripheral edema, shortness of breath, nocturia, blood in urine, anemia, and infection.

Serious (Less Common but Important)

• Liver injury (elevated liver enzymes, jaundice, hepatitis) - see Precautions and Warnings.
• Interstitial lung disease, presenting as new or worsening cough and shortness of breath.
• Increased bleeding risk in patients on anticoagulants (see Interactions).

Patients taking Bicalutamide should seek prompt medical attention for yellowing of the skin/eyes, severe abdominal pain, unusual bleeding, or breathing difficulty.